Drug intelligence / Profile preview

TRN501

Development stage: Phase 1
Lead developer: SNLD
Modality: Small Molecules
Administration: Intranasal

Overview

TRN501 (also referred to as TRN-501) is an investigational drug developed by SNLD for the treatment of Parkinson's disease. It is currently being evaluated in early-phase clinical trials, with a Phase I study completed in healthy volunteers using intranasal administration. The precise mechanism of action for TRN501 has not been publicly defined as of the latest available data. There are no approved indications or known adverse events reported at this stage[2][3][4][5].

Beyond the preview

Go deeper on TRN501.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TRN501.

Explore the full profile